phrykt

Arcus Biosciences, Inc. (RCUS): who owns it and who trades it

As of Nov 16, 2026, RCUS insiders reported 33 open-market sales worth $10M and no purchases in the last 12 months, with 90% of the sale value made under pre-set 10b5-1 plans. The largest seller was Juan C. Jaen (President), with $6.7M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Arcus Biosciences

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RCUS

229 funds and institutions reported RCUS shares worth $3.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Gilead Sciences, Inc. with 25.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Gilead Sciences, Inc.25.0%
BlackRock, Inc.13.1%
State Street Corp4.8%
Wellington Management Group LLP4.7%
Montanova Capital, LLC3.8%
Vanguard Portfolio Management LLC3.6%
FMR LLC (Fidelity)3.2%
Vanguard Capital Management LLC3.1%
Citadel Advisors LLC2.5%
Woodline Partners LP2.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Gilead Sciences, Inc.31.42M24.99%$969MNo change
BlackRock, Inc.16.42M13.05%$506M+8%
State Street Corp6.03M4.79%$186M+11%
Wellington Management Group LLP5.90M4.69%$182M-3%
Montanova Capital, LLC4.78M3.80%$147M-5%
Vanguard Portfolio Management LLC4.48M3.56%$138M+5%
FMR LLC (Fidelity)4.05M3.22%$125M+248%
Vanguard Capital Management LLC3.89M3.09%$120M+1%
Citadel Advisors LLC3.14M2.49%$96.7M+136%
Woodline Partners LP3.01M2.39%$92.7M-20%
California State Teachers Retirement System3.00M2.39%$97.4M+2739%
Geode Capital Management, LLC2.45M1.95%$75.5M+9%
Siren, L.L.C.2.42M1.92%$74.6M-20%
Fisher Asset Management, LLC2.14M1.70%$66M-2%
Marshall Wace, LLP1.95M1.55%$60M-48%
Samlyn Capital, LLC1.55M1.23%$47.7M-19%
Dimensional Fund Advisors LP1.43M1.14%$44.2M+1%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1.42M1.13%$43.8M-14%
Goldman Sachs Group Inc1.39M1.10%$42.8M+39%
Soleus Capital Management, L.P.1.17M0.93%$36M+159%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RCUS insiders reported $0 of open-market purchases and $10M of sales. 90% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$10M
33 trades, 7 people
Sales under a 10b5-1 plan
90%
Share of sale value
Latest trade
Aug 21, 2026
Filed Aug 24, 2026

Purchases and sales by month

$4.9M$4.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 21, 2026Alexander AzoyChief Accounting OfficerSale plan2,827$30.00$84.8KForm 4
Jul 10, 2026Juan C. JaenPresidentSale plan268$29.40$7.9KForm 4
Jul 10, 2026Juan C. JaenPresidentSale plan19,799$28.61$566KForm 4
Jul 9, 2026Juan C. JaenPresidentSale plan48,502$30.05$1.5MForm 4
Jun 24, 2026Juan C. JaenPresidentSale6,431$29.66$191KForm 4
Jun 23, 2026Juan C. JaenPresidentSale1,697$28.06$47.6KForm 4
Jun 23, 2026Juan C. JaenPresidentSale14,067$27.69$390KForm 4
Jun 22, 2026Juan C. JaenPresidentSale9,236$27.03$250KForm 4
Jun 1, 2026Alexander AzoyChief Accounting OfficerSale plan2,562$25.77$66KForm 4
May 11, 2026Robert C. Goeltz IICFOSale plan7,763$25.63$199KForm 4
Jan 5, 2026Juan C. JaenPresidentSale plan2,053$22.34$45.9KForm 4
Jan 5, 2026Juan C. JaenPresidentSale plan29,670$21.34$633KForm 4
Jan 5, 2026Juan C. JaenPresidentSale plan100$23.20$2.3KForm 4
Dec 31, 2025Robert C. Goeltz IICFOSale6,552$23.38$153KForm 4
Dec 18, 2025Alexander AzoyChief Accounting OfficerSale plan4,343$22.25$96.6KForm 4
Dec 17, 2025Carolyn C. TangGeneral CounselSale plan6,810$22.16$151KForm 4
Dec 17, 2025Richard MarkusChief Medical OfficerSale plan4,494$22.16$99.6KForm 4
Dec 17, 2025Alexander AzoyChief Accounting OfficerSale plan2,113$22.16$46.8KForm 4
Dec 17, 2025Robert C. Goeltz IICFOSale plan5,960$22.16$132KForm 4
Dec 17, 2025Jennifer JarrettChief Operating OfficerSale plan9,983$22.16$221KForm 4
Dec 17, 2025Terry J RosenCEOSale plan25,744$22.16$570KForm 4
Dec 16, 2025Carolyn C. TangGeneral CounselSale plan7,658$21.88$168KForm 4
Dec 16, 2025Richard MarkusChief Medical OfficerSale plan5,052$21.88$111KForm 4
Dec 16, 2025Alexander AzoyChief Accounting OfficerSale plan2,376$21.88$52KForm 4
Dec 16, 2025Robert C. Goeltz IICFOSale plan6,702$21.88$147KForm 4
Dec 16, 2025Jennifer JarrettChief Operating OfficerSale plan11,225$21.88$246KForm 4
Dec 16, 2025Terry J RosenCEOSale plan28,947$21.88$633KForm 4
Dec 4, 2025Juan C. JaenPresidentSale plan82,997$24.71$2.1MForm 4
Nov 26, 2025Alexander AzoyChief Accounting OfficerSale plan1,900$26.00$49.4KForm 4
Nov 26, 2025Robert C. Goeltz IICFOSale plan5,000$25.00$125KForm 4
Nov 18, 2025Juan C. JaenPresidentSale plan5,050$19.75$99.7KForm 4
Nov 17, 2025Juan C. JaenPresidentSale plan37,114$20.23$751KForm 4
Nov 17, 2025Juan C. JaenPresidentSale plan7,836$20.71$162KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Juan C. JaenPresident–$6.7MJul 10, 2026
Terry J RosenChief Executive Officer, Director–$1.2MDec 17, 2025
Robert C. Goeltz IIChief Financial Officer–$756KMay 11, 2026
Jennifer JarrettChief Operating Officer–$467KDec 17, 2025
Alexander AzoyChief Accounting Officer–$396KAug 21, 2026
Carolyn C. TangGeneral Counsel–$318KDec 17, 2025
Richard MarkusChief Medical Officer–$210KDec 17, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RCUS short interest

Moderate short interest. 9.2% of RCUS shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 21%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 13.18M RCUS shares were sold short, 9.2% of the shares outstanding, up 6.6% from the report before. At the average daily volume of 3.70M shares, buying them all back would take about 3.6 trading days (days to cover).

Shares short, % of all shares

9.15%May 15Oct 3011.2%

Days to cover

3.6May 15Oct 3014.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202613.18M9.15%+7%3.70M3.6
Oct 15, 202612.36M9.71%-6%1.28M9.7
Sep 30, 202613.11M10.30%-5%1.72M7.6
Sep 15, 202613.81M10.85%+6%1.77M7.8
Aug 31, 202613.08M10.27%-6%1.19M11.0
Aug 14, 202613.85M10.88%+6%1.13M12.3
Jul 31, 202613.12M10.30%+4%1.13M11.6
Jul 15, 202612.56M9.99%-1%972,34912.9
Jun 30, 202612.64M10.05%-5%2.14M5.9
Jun 15, 202613.27M10.55%+13%1.22M10.9
May 29, 202611.71M9.31%+8%929,32712.6
May 15, 202610.89M8.66%+0%970,67111.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Arcus Biosciences company events

Arcus Biosciences filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Oct 23, 2026AnnouncementArcus Biosciences, Inc. entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein, relating to the public offering, issuance and sale of 14,285,715 shares of the Company’s common stock… Filing
  3. Oct 21, 2026ResultsReleased financial results. Filing
  4. Oct 20, 2026AnnouncementArcus Biosciences, Inc. presented new data from the ARC-20 platform study evaluating casdatifan, alone or in combination, as a first-, second- and late-line treatment for clear cell renal cell carcinoma. Filing
  5. Aug 5, 2026ResultsReleased financial results. Filing
  6. Jun 12, 2026VoteReported shareholder vote results. Filing
  7. May 5, 2026ResultsReleased financial results. Filing
  8. Apr 20, 2026AnnouncementArcus Biosciences, Inc. announced the discontinuation of the Phase 3 STAR-121 study, which is being conducted in collaboration with Gilead Sciences, Inc., due to futility. Filing
  9. Mar 23, 2026LeadershipJennifer Jarrett notified Arcus Biosciences, Inc. of her decision to resign from her position as Chief Operating Officer, effective as of March 30, 2026. Filing
  10. Feb 25, 2026ResultsReleased financial results. Filing
  11. Dec 18, 2025AgreementArcus Biosciences, Inc. entered into a First Amendment to the Loan and Security Agreement with the several banks and other financial institutions or entities party thereto, as lenders, and Hercules Capital, Inc., as administrative agent and collateral agent. Filing
  12. Dec 12, 2025AnnouncementArcus Biosciences, Inc. announced the discontinuation of the Phase 3 STAR-221 study due to futility. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Arcus Biosciences financials

Famous investors that hold RCUS

6 of the 50 well-known investors we track reported holding RCUS in their latest 13F filing. The largest position is Ken Griffin's, worth $76.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20262.96M$76.5M0.0%-6%
Ken Fisher · Fisher Asset ManagementQ3 20261.92M$49.6M0.0%-10%
Steve Cohen · Point72 Asset ManagementQ3 2026202,458$5.2M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 2026131,221$3.4M0.0%New
Jim Simons · Renaissance TechnologiesQ3 2026102,500$2.6M0.0%New
Israel Englander · Millennium ManagementQ3 202699,037$2.6M0.0%-26%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Arcus Biosciences, Inc. (RCUS) stock

Who owns the most RCUS stock?

The largest reported owner of Arcus Biosciences, Inc. (RCUS) is Gilead Sciences, Inc., with 25.0% of the company. In total, 229 funds and institutions reported holding RCUS at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are RCUS insiders buying or selling?

In the last 12 months, RCUS insiders reported no open-market purchases and 33 sales worth $10M. The latest trade was on Aug 21, 2026. See every trade.

What is the short interest in RCUS?

As of Oct 30, 2026, 13.18M RCUS shares were sold short, 9.2% of the shares outstanding, up 6.6% from the report before. At the average daily volume of 3.70M shares, buying them all back would take about 3.6 trading days (days to cover). See the history.

Which famous investors hold RCUS?

6 of the 50 well-known investors we track reported RCUS in their latest 13F filing, including Ken Griffin, Ken Fisher, Steve Cohen. The largest position is worth $76.5M. See all holders.

Executive pay

Arcus Biosciences's chief executive was paid a total of $9.7M for the year ended Dec 31, 2025, up 33% from $7.3M the year before. In the last 12 months, Arcus Biosciences's executives and directors bought no stock on the open market and sold $10M.

Chief executive, total pay$9.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$17.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.